Project Grant R15CA309584
Award Date 4/1/26
Completion Date 3/31/29
Dollars Obligated $535K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Irvine, CA 92618, USA
Similar Awards
- Federal Project Grant Award Summary Chapman University received a $415,500 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), awarded June 19, 2025, with completion targeted for May 31, 2028. The award supports research to develop peptide-doxorubicin (DOX) conjugates as improved chemotherapy delivery systems. Doxorubicin is an FDA-approved anthracycline drug used to treat multiple cancer types, but its clinical application is limited...
- Federal Project Grant Award Summary Chapman University received a $610,415 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) awarded on June 23, 2025, with a completion date of May 31, 2030. This award supports the development of small molecule selective inhibitors of neuronal nitric oxide synthase (nNOS) for melanoma treatment. The research focuses on designing, synthesizing, and evaluating novel nNOS inhibitors with improved...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $615,399 Project Grant to the University of California, Davis under the Cancer Treatment Research program (CFDA 93.395) for the period August 1, 2025, through July 31, 2030. The award supports the development of a transformable nanoparticle (TNP) platform designed to deliver therapeutic peptides and proteins directly to tumor microenvironments on-demand. The TNP technology transforms from nanoparticles to nanofibrils...
- Federal Grant Award Summary Temple University received a $177,209 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on July 18, 2025, with a completion date of June 30, 2027. The award supports research aimed at developing fluorine-thiol displacement reaction (FTDR)-stapled peptide probes to target C-MYC, an undruggable transcription factor implicated in castration-resistant prostate cancer (CRPC) progression. The research...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $482,236 to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2025, with a project completion date of July 31, 2030. This investigator-initiated Phase 2 clinical trial will evaluate the safety and efficacy of combining trastuzumab deruxtecan (T-DXD), an antibody-drug conjugate, with the anti-EGFR (epidermal growth factor receptor)...
- Federal Project Grant Award Summary The University of Tennessee Health Science Center received a $658,561 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), effective August 7, 2025, with a completion date of July 31, 2030. This award supports research focused on targeted MDM2 (Murine Double Minute 2) degradation as an improved therapeutic strategy for triple-negative breast cancer (TNBC). The project centers on optimization and...
- Federal Project Grant Award Summary The University of California, Davis received a $149,394 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) effective August 1, 2025 through July 31, 2030. This award supports research in targeted radiotheranostics—the development and clinical translation of diagnostic and therapeutic radiopharmaceuticals that enable integrated imaging and treatment of cancer. The research encompasses the...
- Federal Project Grant Award Summary Albert Einstein College of Medicine received a $431,970 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026, through March 31, 2028. The award supports research to decipher mechanisms of resistance to anti-TROP2 (tumor-associated glycoprotein 2) antibody-drug conjugates, specifically sacituzumab govitecan (SG), which is currently approved for treating advanced...
- Federal Grant Award Summary Auburn University received a $153,959 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective September 1, 2025, through August 31, 2027. The award supports the development and preclinical evaluation of APD1-4-1BBL, a bispecific fusion protein designed to enhance the safety and efficacy of combination immune checkpoint therapies. The project involves engineering and testing three murinized and...